MEDICURE INC. ACQUIRES U.S. RIGHTS TO AGGRASTAT FROM MGI PHARMA, INC.

Medicure Inc., a cardiovascular focused biopharmaceutical company, announced that the company has acquired the exclusive U.S. rights to AGGRASTAT Injection (tirofiban hydrochloride) from MGI PHARMA, INC. AGGRASTAT, a glycoprotein (GP) IIb/IIIa inhibitor, is used for the treatment of acute coronary syndrome (ACS) including unstable angina and non-Q-wave myocardial infarction.
BioSpace